Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Fukuda, Shin ^a   Kohsaka, Hitoshi ^a   Takayasu, Aiko ^a   Yokoyama, Waka ^a   Miyabe, Chie ^a,b   Miyabe, Yoshishige ^a   Harigai, Masayoshi ^a   Miyasaka, Nobuyuki ^a   Nanki, Toshihiro ^a,c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

Author keywords

Cannabinoid; Cannabinoid receptor 2 (CB2); Fibroblast like synoviocyte; JWH133; Monocyte; Rheumatoid arthritis

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CANNABINOID 2 RECEPTOR; COLLAGEN TYPE 2; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 17; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; CANNABINOID; CNR2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; RHEUMATOID ARTHRITIS; SPLEEN CELL; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING; AGONISTS; ANIMAL; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; CELL CULTURE; DBA MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; MALE; METABOLISM; MIDDLE AGED; MOUSE;

ADULT; AGED; ANIMALS; ARTHRITIS, RHEUMATOID; CANNABINOIDS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MICE; MICE, INBRED DBA; MIDDLE AGED; RECEPTOR, CANNABINOID, CB2; SYNOVIAL MEMBRANE;

EID: 84906931347     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-275     Document Type: Article

References (38)

1. The pathogenesis of rheumatoid arthritis. McInnes IB, Schett G, N Engl J Med 2011 365 23 2205 2219
2. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, Nature 1990 346 6284 561 564
3. Molecular characterization of a peripheral receptor for cannabinoids. Munro S, Thomas KL, Abu-Shaar M, Nature 1993 365 6441 61 65
4. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton JA, Pertwee RG, Eur J Pharmacol 1997 339 1 53 61
5. The orphan receptor GPR55 is a novel cannabinoid receptor. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ, Br J Pharmacol 2007 152 7 1092 1101
6. GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Gasperi V, Dainese E, Oddi S, Sabatucci A, Maccarrone M, Curr Med Chem 2013 20 1 64 78
7. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, Sanchez C, Waldhoer M, Mol Endocrinol 2011 25 11 1835 1848
8. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). McVey DC, Schmid PC, Schmid HH, Vigna SR, J Pharmacol Exp Ther 2003 304 2 713 722
9. TRPV4 calcium entry channel: a paradigm for gating diversity. Nilius B, Vriens J, Prenen J, Droogmans G, Voets T, Am J Physiol Cell Physiol 2004 286 2 195 C205
10. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. O'Sullivan SE, Br J Pharmacol 2007 152 5 576 582
11. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Croxford JL, Yamamura T, J Neuroimmunol 2005 166 1-2 3 18
12. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M, Arthritis Rheum 2004 50 3 985 998
13. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH, Pharmacol Biochem Behav 2011 99 4 718 725
14. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR, Bioorg Med Chem 1999 7 12 2905 2914
15. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Elmes SJ, Jhaveri MD, Smart D, Kendall DA, Chapman V, Eur J Neurosci 2004 20 9 2311 2320
16. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial. Lee EY, Lee EB, Park BJ, Lee CK, Yoo B, Lim MK, Shim SC, Sheen DH, Seo YI, Kim HA, Baek HJ, Song YW, Clin Ther 2006 28 12 2052 2060
17. - 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al. Arthritis Rheum 2010 62 9 2569 2581
18. Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. Kaneko K, Miyabe Y, Takayasu A, Fukuda S, Miyabe C, Ebisawa M, Yokoyama W, Watanabe K, Imai T, Muramoto K, Terashima Y, Sugihara T, Matsushima K, Miyasaka N, Nanki T, Arthritis Res Ther 2011 13 5 158
19. The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis. Sato A, Watanabe K, Kaneko K, Murakami Y, Ishido M, Miyasaka N, Nanki T, Mod Rheumatol 2010 20 3 244 251
20. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P, Eur J Biochem 1995 232 1 54 61
21. CB2 receptor-mediated migration of immune cells: it can go either way. Miller AM, Stella N, Br J Pharmacol 2008 153 2 299 308
22. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB, J Cell Biochem 2007 100 1 184 190
23. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Montecucco F, Burger F, Mach F, Steffens S, Am J Physiol Heart Circ Physiol 2008 294 3 1145 H1155
24. Medicinal use of cannabis: history and current status. Kalant H, Pain Res Manag 2001 6 2 80 91
25. Therapeutic targeting of the interleukin-6 receptor. Tanaka T, Narazaki M, Kishimoto T, Annu Rev Pharmacol Toxicol 2012 52 199 219
26. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group, Arthritis Rheum 2006 54 9 2817 2829
27. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J, Ann Rheum Dis 2012 71 7 1183 1189
28. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G, Eur Cytokine Netw 2005 16 4 289 292
29. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE, Arthritis Res 2001 3 2 118 126
30. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1beta. Ainola MM, Mandelin JA, Liljeström MP, Li TF, Hukkanen MV, Konttinen YT, Clin Exp Rheumatol 2005 23 5 644 650
31. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. Condie R, Herring A, Koh WS, Lee M, Kaminski NE, J Biol Chem 1996 271 22 13175 13183
32. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. Börner C, Smida M, Höllt V, Schraven B, Kraus J, J Biol Chem 2009 284 51 35450 35460
33. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA, J Neuroimmune Pharmacol 2008 3 2 117 129
34. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. Cencioni MT, Chiurchiù V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M, PLoS One 2010 5 1 8688
35. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Ghosh S, Preet A, Groopman JE, Ganju RK, Mol Immunol 2006 43 14 2169 2179
36. Peripheral cannabinoid receptor, CB2, regulates bone mass. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I, Proc Natl Acad Sci U S A 2006 103 3 696 701
37. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. Nakae S, Nambu A, Sudo K, Iwakura Y, J Immunol 2003 171 11 6173 6177
38. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S: T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204(1):4147.